WO2008144483A3 - Agents for treating disorders involving modulation of ryanodine receptors - Google Patents
Agents for treating disorders involving modulation of ryanodine receptors Download PDFInfo
- Publication number
- WO2008144483A3 WO2008144483A3 PCT/US2008/063857 US2008063857W WO2008144483A3 WO 2008144483 A3 WO2008144483 A3 WO 2008144483A3 US 2008063857 W US2008063857 W US 2008063857W WO 2008144483 A3 WO2008144483 A3 WO 2008144483A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- agents
- treating disorders
- disorders involving
- ryanodine receptors
- involving modulation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Abstract
The present invention provides new agents and compounds effective for treating disorders and diseases associated with RyRs, including cardiac, muscular and cognitive disorders and diseases. These agents are derivatives of benzoxazepines, benzodiazepines and benzazapines. More particularly, the invention provides compounds which include derivatives of benzoxazepine, and their enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, hydrates, solvates, complexes, polymorphs, metabolites, and prodrugs thereof.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW097118419A TW200902026A (en) | 2007-05-18 | 2008-05-19 | Agents for treating disorders involving modulation of ryanodine receptors |
ARP080102126A AR067845A1 (en) | 2007-05-18 | 2008-05-19 | COMPOUNDS TO TREAT DISORDERS RELATED TO THE MODULATION OF RIANODINE RECEPTORS AND PHARMACEUTICAL COMPOSITION |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US93076307P | 2007-05-18 | 2007-05-18 | |
US60/930,763 | 2007-05-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008144483A2 WO2008144483A2 (en) | 2008-11-27 |
WO2008144483A3 true WO2008144483A3 (en) | 2012-08-16 |
Family
ID=40122265
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/063857 WO2008144483A2 (en) | 2007-05-18 | 2008-05-16 | Agents for treating disorders involving modulation of ryanodine receptors |
Country Status (3)
Country | Link |
---|---|
AR (1) | AR067845A1 (en) |
TW (1) | TW200902026A (en) |
WO (1) | WO2008144483A2 (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8710045B2 (en) | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
US20090012103A1 (en) | 2007-07-05 | 2009-01-08 | Matthew Abelman | Substituted heterocyclic compounds |
WO2010053757A1 (en) | 2008-10-29 | 2010-05-14 | Gilead Palo Alto, Inc. | 2 -oxoquinoxalin blockers of the late sodium channel |
US20100113514A1 (en) | 2008-10-30 | 2010-05-06 | Gilead Palo Alto, Inc. | Fused heterocyclic compounds as ion channel modulators |
WO2010056865A1 (en) | 2008-11-14 | 2010-05-20 | Gilead Palo Alto, Inc. | Quinoline derivatives as ion channel modulators |
CA2763099A1 (en) | 2009-05-22 | 2010-11-25 | Exelixis, Inc. | Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases |
BRPI1010896A2 (en) | 2009-05-26 | 2019-09-24 | Exelixis Inc | benzoxazepines as pi3k / mtor inhibitors and methods of their use and manufacture |
WO2010138490A1 (en) * | 2009-05-26 | 2010-12-02 | Exelixis, Inc. | Benzoxazepines as inhibitors of mtor and methods of their use and manufacture |
HUE034911T2 (en) | 2009-07-27 | 2018-03-28 | Gilead Sciences Inc | Fused heterocyclic compounds as ion channel modulators |
CN103096977B (en) | 2010-07-02 | 2017-02-15 | 吉利德科学公司 | Fused heterocyclic compounds as ion channel modulators |
WO2012019071A1 (en) * | 2010-08-06 | 2012-02-09 | The Trustees Of Columbia University In The City Of New York | Methods of preventing and treating sarcopenia |
US9115096B2 (en) | 2011-05-10 | 2015-08-25 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
AU2015224425B2 (en) * | 2011-07-01 | 2017-02-09 | Gilead Sciences, Inc. | Fused benzoxazepinones as ion channel modulators |
AU2013201608B9 (en) * | 2011-07-01 | 2015-07-23 | Gilead Sciences, Inc. | Fused benzoxazepinones as ion channel modulators |
UY34171A (en) * | 2011-07-01 | 2013-01-31 | Gilead Sciences Inc | FUSIONED HETEROCYCLIC COMPOUNDS AS IONIC CHANNEL MODULATORS |
NO3175985T3 (en) | 2011-07-01 | 2018-04-28 | ||
EP2806865A1 (en) * | 2012-01-27 | 2014-12-03 | Gilead Sciences, Inc. | Combination therapies using late sodium ion channel blockers and potassium ion channel blockers |
CN105829301A (en) * | 2013-12-19 | 2016-08-03 | 吉利德科学公司 | Fused heterocyclic compounds as ion channel modulators |
ES2643856B1 (en) | 2016-05-24 | 2018-08-03 | Universidad Del Pais Vasco / Euskal Herriko Unibertsitatea | Triazoles for the regulation of intracellular calcium homeostasis |
CA3048376A1 (en) | 2016-12-27 | 2018-07-05 | Riken | Bmp-signal-inhibiting compound |
JP2024503045A (en) | 2021-01-08 | 2024-01-24 | アームゴ・ファーマ・インコーポレーテッド | Crystal forms of ryanodine receptor modulators and their uses |
WO2022246114A2 (en) | 2021-05-20 | 2022-11-24 | Armgo Pharma, Inc. | Pharmaceutical compositions comprising a ryanodine receptor modulator and uses thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4125538A (en) * | 1977-02-04 | 1978-11-14 | Bristol-Myers Company | Substituted 5-phenyl-2,3,4,5-tetrahydro-1,4-benzoxazepines |
US4592866A (en) * | 1982-09-30 | 1986-06-03 | A. H. Robins Company, Inc. | Fused aromatic oxazepinones, thiazepinones, diazepinones and sulfur analogs thereof |
WO1998047876A1 (en) * | 1997-04-24 | 1998-10-29 | Akzo Nobel N.V. | Heterocyclic derivatives and their use as antithrombotic agents |
US6489322B1 (en) * | 1997-05-05 | 2002-12-03 | Astrazeneca Ab | Amidine derivatives as inhibitors of nitric oxide synthase |
WO2007024717A2 (en) * | 2005-08-25 | 2007-03-01 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryr receptors |
-
2008
- 2008-05-16 WO PCT/US2008/063857 patent/WO2008144483A2/en active Application Filing
- 2008-05-19 AR ARP080102126A patent/AR067845A1/en unknown
- 2008-05-19 TW TW097118419A patent/TW200902026A/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4125538A (en) * | 1977-02-04 | 1978-11-14 | Bristol-Myers Company | Substituted 5-phenyl-2,3,4,5-tetrahydro-1,4-benzoxazepines |
US4592866A (en) * | 1982-09-30 | 1986-06-03 | A. H. Robins Company, Inc. | Fused aromatic oxazepinones, thiazepinones, diazepinones and sulfur analogs thereof |
WO1998047876A1 (en) * | 1997-04-24 | 1998-10-29 | Akzo Nobel N.V. | Heterocyclic derivatives and their use as antithrombotic agents |
US6489322B1 (en) * | 1997-05-05 | 2002-12-03 | Astrazeneca Ab | Amidine derivatives as inhibitors of nitric oxide synthase |
WO2007024717A2 (en) * | 2005-08-25 | 2007-03-01 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryr receptors |
Non-Patent Citations (2)
Title |
---|
ISHICHI Y ET AL: "Novel acetylcholinesterase inhibitor as increasing agent on rhythmic bladder contractions: SAR of 8-{3-[1-(3-fluorobenzyl)piperidin-4-yl]p ropanoyl}-1,2,5,6-tetrahydro-4H-pyrr olo[3,2,1-ij]quinolin-4-one (TAK-802) and related compounds", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 13, no. 6, 15 March 2005 (2005-03-15), pages 1901 - 1911, XP004758992, ISSN: 0968-0896, DOI: 10.1016/J.BMC.2005.01.022 * |
PATANI G A ET AL: "BIOISOSTERISM: A RATIONAL APPROACH IN DRUG DESIGN", CHEMICAL REVIEWS, AMERICAN CHEMICAL SOCIETY, US, vol. 96, no. 8, 1 January 1996 (1996-01-01), pages 3147 - 3176, XP000652176, ISSN: 0009-2665, DOI: 10.1021/CR950066Q * |
Also Published As
Publication number | Publication date |
---|---|
WO2008144483A2 (en) | 2008-11-27 |
AR067845A1 (en) | 2009-10-28 |
TW200902026A (en) | 2009-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008144483A3 (en) | Agents for treating disorders involving modulation of ryanodine receptors | |
HK1166078A1 (en) | Pyrimidyl cyclopentanes as akt protein kinase inhibitors akt | |
WO2009006567A3 (en) | Pyrimidyl cyclopentanes as akt protein kinase inhibitors | |
MY147628A (en) | Cyclopenta [d] pyrimidines as akt protein kinase inhibitors | |
NZ595738A (en) | Benzimidazole-piperidine-cyclohexane derivatives which have activity at M1 receptor and their uses in medicine | |
ZA200608628B (en) | Substituted morpholine compounds for the treatment of central nervous system disorders | |
WO2008039489A3 (en) | 5-substituted quinazolinone derivatives as antitumor agents | |
WO2010045251A3 (en) | Spiro-oxindole compounds and their use as therapeutic agents | |
IN2014KN02886A (en) | ||
MXPA06009475A (en) | Quinazoline derivatives and therapeutic use thereof. | |
WO2011053938A8 (en) | Methods and compositions for treating cancer | |
IL194076A (en) | Benzo[d]imidazo[2,1-b]thiazol-2-ylphenyl compounds for the treatment of disease | |
NZ593440A (en) | Aminopyrazole compounds useful for inhibiting chk1 | |
DK2054418T3 (en) | Dihydrothienopyrimidines as AKT protein kinase inhibitors | |
MX2013005535A (en) | 3-(aminoaryl)-pyridine compounds. | |
MY157495A (en) | 6-,7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same | |
CR20210626A (en) | Quinazolin-4-one derivatives useful for the treatment of braf-associated diseases and disorders | |
MX2009004096A (en) | Talarazole metabolites. | |
IL191763A0 (en) | Pyrrolo [2,3-b]pyridine derivatives as h3 receptor modulators | |
TW200724143A (en) | Novel compounds for the treatment of inflammatory diseases | |
TW200635592A (en) | Pyridyl-substituted spiro-hydantoin compounds and use thereof | |
TW200633997A (en) | Substituted heterocyclic compounds and thrombopoietin receptor activators | |
MX2010001304A (en) | Therapeutic compounds. | |
IL194390A0 (en) | Heterocyclic gaba alpha subtype selective receptor modulators | |
UA104410C2 (en) | Pyrimidyl cyclopentanes as akt protein kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08755663 Country of ref document: EP Kind code of ref document: A2 |